Beyond Counting on Our Fingers: The Current State and Future Management of Oligometastatic Lung Cancer

There is a high degree of variability in the management and even the understanding of the oligometastatic state in lung malignancies, or indeed in the context of any solid tumor. The activity presents the most up-to-date radiation-focused definitive management of these patients as well as providing information about where the field is headed. 

In this activity we provide up-to-date recommendations for the radiation-focused definitive management of oligometastatic lung cancer, particularly in light of incomplete randomized data (LU-002). This is coupled with a detailed review of current clinical and translational research focused on understanding the oligometastatic state as well as novel combinatorial approaches utilizing radiation in this setting. Specifically, novel uses of radiation are discussed as well as radiation combinations with both novel immunotherapeutic or other targeted therapies. 

Topics:

  1. Defining and Understanding the Oligometastatic State
    Jing Zeng, MD
  2. The Definitive Management of Oligometastatic Disease
    Daniel R. Gomez, MD
  3. Q and A
    Full Panel
  4. Novel Combinatorial Uses of Radiation in Oligometastatic Disease
    Heath D. Skinner, MD, PhD

This activity is available from December 17, 2024, through 11:59 p.m. Eastern time on December 16, 2026. 

This activity was originally recorded at the 2024 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists, radiation biologists and residents.  

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the most up-to-date uses of radiation in oligometastatic lung cancer. 
  • Explain the current definition and biomarkers of oligometastatic disease and their limitations.
  • Discuss novel uses of radiation and combinatorial approaches in the oligometastatic setting. 
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
12/17/2024
Course expires: 
12/16/2026
Cost:
$149.00
Rating: 
0
  • Heath D. Skinner, MD, PhD, is employed by UPMC Hillman Cancer Center. Dr. Skinner receives grant/research funding from NIDCR/NIH and EMD Soreno. Dr. Skinner serves as a member of the head and neck steering committee with the National Cancer Institute and is a programmatic review committee member with the Department of Defense Congressionally Directed Medical Research Program (CDMRP). 
  • Jing Zeng, MD, is employed by University of Washington, Fred Hutchinson Cancer Center. Dr. Zeng receives grant/research funding, honoraria and compensation from IBA, AstraZeneca, NIH, Kuni Foundation and Gilead. 
  • Daniel R. Gomez, MD, is employed by Memorial Sloan Kettering Cancer Center. Dr. Gomez receives grant/research funding and honoraria from AstraZeneca, Varian, Johnson and Johnson, Medtronic, Merck and GRAIL. 

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

Disclosure link: 
ASTRO Education Committee

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
 

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.  

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until December 16, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.